ArticleERJ open research2026

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

Jonathan Corren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.